Ann: Mesoblast Update on COVID-19 ARDS Trial, page-221

Well that's not a corporate update as stated in the trading halt and not a good look at all that it took two trading days to write an underwhelming announcement.

The cash burn for manufacturing, marketing etc in the last quarter was significant as well, and it would seem now unlikely to translate into a return on that investment.

Its disappointing for sure but these costly lessons aren't entirely a bad thing long term as the underpinning science behind MSB products is becoming more widely known and credible.

As a long term holder I have no intention of walking away now but respect each investor has a different risk appetite and profile so can't be critical of those that may be tempted to jump on this outcome because it's a fairly bitter pill this result.

But not particularly pleased with the wording of the halt and the time they took to write not much at all. They are better than that particularly with the suite of advisors they've accumulated.